CN106928118B - Method for preparing silodosin intermediate - Google Patents

Method for preparing silodosin intermediate Download PDF

Info

Publication number
CN106928118B
CN106928118B CN201710231920.8A CN201710231920A CN106928118B CN 106928118 B CN106928118 B CN 106928118B CN 201710231920 A CN201710231920 A CN 201710231920A CN 106928118 B CN106928118 B CN 106928118B
Authority
CN
China
Prior art keywords
reaction
zinc powder
silodosin intermediate
formula
preparing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201710231920.8A
Other languages
Chinese (zh)
Other versions
CN106928118A (en
Inventor
史卫明
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Changzhou Ruiming Pharmaceutical Co ltd
Original Assignee
Changzhou Ruiming Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Changzhou Ruiming Pharmaceutical Co ltd filed Critical Changzhou Ruiming Pharmaceutical Co ltd
Priority to CN201710231920.8A priority Critical patent/CN106928118B/en
Publication of CN106928118A publication Critical patent/CN106928118A/en
Application granted granted Critical
Publication of CN106928118B publication Critical patent/CN106928118B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/08Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/584Recycling of catalysts

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)

Abstract

The invention provides a method for preparing silodosin intermediate, which has a structural formula shown as a formula (I):
Figure DDA0001266848720000011
the preparation method comprises the following steps: taking benzoic acid 3- (7-cyano-5- (2-nitropropyl) indoline-1-yl) propyl ester (II) as a raw material, and reducing in a zinc powder/hydrochloric acid system to obtain a silodosin intermediate (I), wherein the reduction reaction formula is as follows:

Description

Method for preparing silodosin intermediate
Technical Field
The invention belongs to the field of medicine research, and particularly relates to a method for preparing a silodosin intermediate.
Background
The invention relates to a method for preparing silodosin intermediate benzoic acid-3- (5- (2-aminopropyl) -7-cyanoindolin-1-yl) propyl ester (I). Silodosin is a drug for treating benign prostatic hyperplasia, has a remarkable curative effect and small side effects, and is popular with patients in various countries. The structural formula is as follows:
Figure BDA0001266848710000011
the invention relates to an important intermediate compound (I) for preparing silodosin
Figure BDA0001266848710000012
The reaction equation involved in the invention is as follows:
Figure BDA0001266848710000013
the reaction for preparing the compound (I) from the compound (II) has been reported in various documents, and mainly includes the following two main groups: the first type is a catalytic hydrogenation or hydrogen transfer process: journal of Medicinal Chemistry, 2016, 59(8), 3826-3839 reports that methanol and tetrahydrofuran are used as solvents, Pd/C is used as a catalyst, catalytic hydrogenation is carried out, and the product is obtained after reaction for 48 hours at 40 ℃; india patent 2013DE01072 reports that methanol and ethyl acetate are used as a mixed solvent, palladium hydroxide is used as a catalyst, and the target product is obtained by catalytic hydrogenation at 50-55 ℃; PCT patent WO2014167507 discloses that methanol and ethyl acetate are used as a mixed solvent, Pd (OH)2 is used as a catalyst, and hydrogenation reaction is carried out at 50-55 ℃ and 10atm H2 to obtain a target product. PCT patent WO2013056842 discloses a target product obtained by catalytic hydrogenation for 8-10h at 25-30 ℃ under the condition of 8-10bar by using Pt as a catalyst and ethyl acetate as a catalyst. Chinese patent CN102746210 reports that a target product is obtained by carrying out catalytic hydrogenation reaction for 10 hours at 50 ℃ and under 0.5MPa by taking Pd as a catalyst and methanol and tetrahydrofuran as a mixed solvent; PCT patent WO2012147107 discloses a method of using Ni as a catalyst, CaCO3 as a carrier, and methanol as a solvent, and performing catalytic hydrogenation to obtain a target product; PCT patent WO2011124704 reports that a target product is obtained by using water, ethanol and DMF as solvents, Pd/C as a catalyst and ammonium formate as a hydrogen transfer reagent.
The second type is a metal reduction method: indian patent 2015CH06154 discloses an iron powder/acetic acid system reduced with ethyl acetate and water as solvents to obtain the target product (I).
Disclosure of Invention
The invention aims at solving the problems that a plurality of methods for preparing a compound (I) reported in the above documents generally need high-pressure equipment, increase potential safety hazard and generally have long reaction time, a cyano group which is easy to hydrogenate is also contained in the compound (I), and impurities which are difficult to separate are easily generated due to over hydrogenation, and a reported metal reduction method takes iron powder as a reducing agent, ferrous salts generated after the reduction of the iron powder can be oxidized into ferric salts in the presence of trace oxygen, and the latter can easily oxidize the product (I) to generate a small amount of nitrogen oxidation products which are difficult to separate.
The technical scheme of the invention is as follows: a process for the preparation of silodosin intermediates having the formula (I):
Figure BDA0001266848710000021
the preparation method comprises the following steps: taking benzoic acid 3- (7-cyano-5- (2-nitropropyl) indoline-1-yl) propyl ester (II) as a raw material, and reducing in a zinc powder/hydrochloric acid system to obtain a silodosin intermediate (I), wherein the reduction reaction formula is as follows:
Figure BDA0001266848710000022
in the above scheme, the reduction reaction is carried out in an organic solvent.
In the scheme, the temperature range of the reduction reaction is 20-120 ℃, and the reaction time is up to the consumption of the raw material (II).
In the scheme, the zinc powder and the hydrochloric acid are in excess compared with the compound (II).
Compared with the prior art, the invention has the beneficial effects that: compared with a hydrogenation method, the zinc powder reduction method of the reaction does not need special equipment, can be smoothly finished by a common reaction kettle, and can not reduce cyano groups to cause the product purity to be poor; compared with the iron powder method, the method has the advantages that the metal mud is easier to remove, and the nitrogen oxide products which are difficult to separate are not generated, so that the method is more beneficial to industrial production.
Detailed Description
EXAMPLE 1 preparation of the Compound benzoic acid-3- (5- (2-aminopropyl) -7-cyanoindolin-1-yl) propyl ester (I)
Adding a raw material (II) and hydrochloric acid into an organic solvent, heating to a certain temperature, slowly adding zinc powder in batches, detecting by thin-layer chromatography (TLC) or High Performance Liquid Chromatography (HPLC) until the raw material (II) completely reacts, filtering, washing a filter cake by using the solvent until the product (I) is not contained, separating and purifying by conventional means such as concentration, washing, drying, salifying and the like to obtain a salt of the compound (I), and alkalifying to obtain the free base of the compound (I). 1 H NMR(400MHz,MeOD)δ8.06-8.00(m,2H),7.63-7.56(m,1H),7.49-7.42(m,2H),7.02(d,J=1.5Hz,1H),6.95(s,1H),4.45(t,J=6.2Hz,2H),3.76(t,J=7.1Hz,2H),3.61(t,J=8.7Hz,2H),3.06-2.90(m,3H),2.54-2.38(m,2H),2.21-2.08(m,2H),1.06(d,J=6.4Hz,3H); 13 C NMR(126MHz,MeOD)δ168.02,153.13,134.60,134.20,132.32,131.32,130.95,130.63,129.50,120.56,88.48,63.97,54.14,49.27,46.36,45.34,28.16,27.86,22.45,ESI-MS:364(M+H + ),386(M+Na + )。
Example 2 examination of the Effect of different temperatures on the reaction
The method of example 1 was used, 95% ethanol was used as solvent, zinc powder and hydrochloric acid were both doubled in excess, and the effect of different temperatures on the reaction was examined, as shown in table 1:
TABLE 1 Effect of different temperatures on the reduction reaction
Figure BDA0001266848710000031
As can be seen from Table 1, when the temperature exceeds 60 ℃, the selectivity of the reaction is significantly decreased, resulting in a lower yield; when the temperature is low (such as 30 ℃ to 40 ℃), the yield is satisfactory, but the reaction rate is slow, the reaction time is too long, and the practical value is reduced, so that the temperature is preferably 50 ℃ to 60 ℃.
Example 3 examination of the Effect of different molar ratios on the reaction
The method of example 1 is adopted, 95% ethanol is used as a solvent, the reaction is carried out at 50 ℃, the influence of the molar ratio of different zinc powders to the raw material (II) on the reaction is examined, and the specific results are shown in Table 2:
TABLE 2 Effect of different molar ratios on the reduction reaction
Figure BDA0001266848710000041
As is clear from Table 2, when the molar ratio is 1.5 or more, the selectivity of the reaction approaches 100%. But continues to increase without significant effect on yield.

Claims (3)

1. A process for the preparation of silodosin intermediate, wherein the intermediate has the formula (I):
Figure FDA0003611834940000011
the preparation method comprises the following steps: taking benzoic acid 3- (7-cyano-5- (2-nitropropyl) indoline-1-yl) propyl ester (II) as a raw material, and reducing in a zinc powder/hydrochloric acid system to obtain a silodosin intermediate (I), wherein the reduction reaction formula is as follows:
Figure FDA0003611834940000012
the temperature range of the reduction reaction is 20-120 ℃, and the reaction time is up to the consumption of the raw material (II).
2. The method for preparing silodosin intermediate according to claim 1, wherein the reduction reaction is performed in an organic solvent.
3. The process for preparing silodosin intermediate as claimed in claim 1, wherein the zinc powder and hydrochloric acid are in excess of compound (II).
CN201710231920.8A 2017-04-11 2017-04-11 Method for preparing silodosin intermediate Active CN106928118B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710231920.8A CN106928118B (en) 2017-04-11 2017-04-11 Method for preparing silodosin intermediate

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710231920.8A CN106928118B (en) 2017-04-11 2017-04-11 Method for preparing silodosin intermediate

Publications (2)

Publication Number Publication Date
CN106928118A CN106928118A (en) 2017-07-07
CN106928118B true CN106928118B (en) 2022-08-23

Family

ID=59426338

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201710231920.8A Active CN106928118B (en) 2017-04-11 2017-04-11 Method for preparing silodosin intermediate

Country Status (1)

Country Link
CN (1) CN106928118B (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102702067A (en) * 2012-06-18 2012-10-03 北京联本医药化学技术有限公司 Novel intermediate for synthesizing silodosin as well as preparation method and purpose of novel intermediate
WO2013056842A1 (en) * 2011-10-21 2013-04-25 Sandoz Ag Method for preparing silodosin
CN104326963A (en) * 2013-07-22 2015-02-04 中国科学院上海药物研究所 Indoline-like compound and preparation method, pharmaceutical composition and application thereof
WO2016189552A2 (en) * 2015-05-26 2016-12-01 Ipca Laboratories Limited Novel recovery and recycling process of unwanted enantiomers of 2-aminopropyl indoline derivatives

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012131710A2 (en) * 2011-03-30 2012-10-04 Panacea Biotec Ltd Novel process for the synthesis of indoline derivatives

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013056842A1 (en) * 2011-10-21 2013-04-25 Sandoz Ag Method for preparing silodosin
CN102702067A (en) * 2012-06-18 2012-10-03 北京联本医药化学技术有限公司 Novel intermediate for synthesizing silodosin as well as preparation method and purpose of novel intermediate
CN104326963A (en) * 2013-07-22 2015-02-04 中国科学院上海药物研究所 Indoline-like compound and preparation method, pharmaceutical composition and application thereof
WO2016189552A2 (en) * 2015-05-26 2016-12-01 Ipca Laboratories Limited Novel recovery and recycling process of unwanted enantiomers of 2-aminopropyl indoline derivatives

Also Published As

Publication number Publication date
CN106928118A (en) 2017-07-07

Similar Documents

Publication Publication Date Title
CN106589037A (en) Method for preparing progesterone and derivatives thereof
CN108129288B (en) Synthesis method of trans-3-hydroxycyclobutylformic acid
EP4169906A1 (en) Method for synthesis of roxadustat and intermediate thereof, and intermediate thereof
CN103420902A (en) Preparation method of 2-chloro-4-iodo-5-methylpyridine
CN106928118B (en) Method for preparing silodosin intermediate
CN108863822B (en) Method for refining isoproterenol hydrochloride
CN102827015B (en) Preparation method of 5-aminolevulinic acid (ALA) hydrochloride
CN105175368B (en) A kind of preparation method of 3 chaff aldehyde product
CN110511117B (en) Method for synthesizing 4-n-butylresorcinol by microchannel reaction
JP5376532B2 (en) Method for producing camptothecin derivative
CN107935971B (en) Preparation method of (S) -3-hydroxytetrahydrofuran
CN107188888A (en) A kind of methanesulfonic acid for preparing steps the auspicious method for Buddhist nun
CN103421004A (en) 5-azaindole preparation method
CN107185571B (en) Cobalt catalyst, preparation method thereof and application thereof in catalytic synthesis of 2,3, 5-trimethylbenzoquinone
CN106749098B (en) A kind of preparation method preparing dioxopromethazine hydrochloride using oxygen as oxidant
CN109851551B (en) Method for synthesizing 3-bromoisonicotinic acid intermediate
CN103992238B (en) The preparation method of 3-aminosallcylic acid
CN102344378B (en) Amino alcohol preparation method using aqueous amino acid
WO2021109099A1 (en) Method for preparing isosorbide 5-mononitrate by using micro-channel continuous flow reactor
CN105503629A (en) Separation method of 16-amino isosteviol ethyl ester diastereoisomer mixture
CN105503828A (en) Preparation method of fumarate of pyrrole derivatives
CN105130972A (en) Emtricitabine benzoate, preparation method thereof, and method of preparing emtricitabine from emtricitabine benzoate
CN111377979A (en) Synthesis method of intermediate bis (carboxycyclopentadiene) iron
CN104804008A (en) Industrial production method of telatinib mesylate
CN111111655B (en) Preparation method of heterogeneous catalyst for selective hydrogenation of 1, 4-butynediol

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant